KLTO: anewmeds.com Future Price to Earnings
The forward P/E valuation of Klotho Neurosciences Inc (KLTO) demonstrates the impact of strategic alliances with dementia research laboratories, where the value of 0.00 corresponds to the current metric. Growth is underpinned by ethical biodata processing within "green" clouds, as well as a stable staff of neurobiologists incentivized by venture options to conduct new clinical trials.
Summary analytical data breakdowns for ANEW Medical, Inc. (KLTO)
- stock value and consensus price forecast:
- market capitalization information:
- balance sheet equity data:
- debt level and financial liquidity data:
Debt to Equity Klotho Neurosciences Inc|KLTO - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Klotho Neurosciences Inc|KLTO - Aggregate Debt Obligations|Debt to Book Capitalization Ratio ANEW Medical|KLTO - Company Long-Term Indebtedness|Company Short-Term Debts Klotho Neurosciences|Quick Liquidity Indicator anewmeds.com
- financial results and valuation multiples details:
KLTO - Net Profit|Expected Profit Klotho Neurosciences Inc|KLTO - Company Value to Net Income|Future Price to Earnings Klotho Neurosciences Inc|KLTO - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ANEW Medical|KLTO - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Klotho Neurosciences|KLTO - Net earnings per share for the last 12 months|Quarterly EPS earnings growth anewmeds.com|KLTO - Expected net earnings per share growth this year|Earnings growth forecast for next year Klotho Neurosciences Inc
Fundamental valuation:KLTO Klotho Neurosciences
The forward P/E determines the market value of a stock relative to expected annual earnings, allowing for the identification of asset overheating or potential undervaluation. By analyzing the NTM forward P/E of Klotho Neurosciences Inc (KLTO), an investor assesses whether the capitalization of Klotho Neurosciences Inc (KLTO) is justified given the commercialization prospects of Klotho protein gene therapies, which are being developed through strategic alliances to combat brain degeneration in Alzheimer's disease.
Who Klotho Neurosciences Inc competes with
Future Price to Earnings Biogen (BIIB)|Future Price to Earnings NBIX (Neurocrine)|Future Price to Earnings Regencell RGC|Axsome Corp (AXSM) - Projected Price to Earnings Ratio|ACAD: Projected Price to Earnings|xenon-pharma.com - Market Cap to Future Earnings Ratio|VKTX: Forward P/E Multiple|Supernus Pharmaceuticals, Inc. - Future Price to Earnings Multiple|Future Price to Earnings Catalyst Pharmaceuticals Inc|Projected Price to Earnings Ratio Denali Corp DNLI|Projected Price to Earnings HRMY (Harmony Biosciences)|BHVN (biohavenpharma.com) - Future Price to Earnings Multiple|Future Price to Earnings Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Price to Future Earnings Ratio|Praxis Medicines - Forward P/E Multiple|Projected Price to Earnings Ratio Anavex Life Sciences Corp|CBLL (CeriBell, Inc.) - Projected Price to Earnings|Prothena (PRTA) - Forward P/E Multiple|Future Price to Earnings Alector Inc.|ANNX: Future Price to Earnings Multiple|Future Price to Earnings Omeros Corporation (OMER)|NGNE - Projected Price to Earnings Ratio|Future Price to Earnings AC Immune ACIU|Market Cap to Projected Earnings voyagertherapeutics.com (VYGR)|Neumora Therapeutics, Inc. - Forward P/E Multiple|Scilex Holding (SCLX) - Projected Price to Earnings|TVGN: Forward P/E Multiple|ACOG - Market Cap to Projected Earnings|CGTX (Cognition Therapeutics) - Forward P/E Multiple|Projected Price to Earnings Ratio inhibikase.com IKT|Future Price to Earnings Cassava Sciences (SAVA)|assertiotx.com - Price to Future Earnings Ratio|Forward P/E Multiple COYA (Coya Therapeutics)|VTGN - Projected Price to Earnings|Ovid Rx - Forward P/E Multiple|Projected Price to Earnings Ratio acumenpharm.com|CervoMed (CRVO) - Future Price to Earnings|ATHE - Market Cap to Projected Earnings|Projected Price to Earnings CLNN|PEPG: Future Price to Earnings Multiple|Forward P/E Multiple JUNS|Market Cap to Projected Earnings relmada.com|Future Price to Earnings Annovis Bio ANVS|GRCE: Price to Future Earnings Ratio|Firefly Neuroscience Inc - Forward P/E Multiple|NeuroSense Therapeutics (NRSN) - Projected Price to Earnings|Reviva Pharmaceuticals (RVPH) - Future Price to Earnings|MetaVia (MTVA) - Forward P/E Multiple|Future Price to Earnings NeurAxis|Future Price to Earnings HSDT|Projected Price to Earnings PASG (Passage Bio, Inc.)|Market Cap to Future Earnings Ratio NEUP|Future Price to Earnings Minerva Neurosciences NERV|athira.com (ATHA) - Projected Price to Earnings Ratio|ADXN - Future Price to Earnings|ALZN (Alzamend Neuro, Inc.) - Price to Future Earnings Ratio|CYCN: Forward P/E Multiple|Projected Price to Earnings Ratio Protagenic Therapeutics, Inc. (PTIX)|Projected Price to Earnings KTTA|Forward P/E Multiple Cortigent Medical|Future Price to Earnings Avenue Therapeutics, Inc. (ATXI)|BCLI (Brainstorm Cell Therapeutics Inc.) - Future Price to Earnings Multiple|Future Price to Earnings Cara Therapeutics, Inc CARA|Chromocell (CHRO) - Projected Price to Earnings Ratio|ELYM - Future Price to Earnings|ITCI - Forward P/E Multiple|Longboard Pharmaceuticals, Inc. (LBPH) - Future Price to Earnings|MRNS (Marinus Pharmaceuticals Inc) - Future Price to Earnings|Future Price to Earnings NKGen|Projected Price to Earnings Ratio NeuroBo Pharma NRBO|Projected Price to Earnings SAGE (Sage Therapeutics, Inc.)|Market Cap to Future Earnings Ratio SNPX|Forward P/E Multiple TRVN (Trevena)|Future Price to Earnings Multiple VIGL|WENA - Future Price to Earnings|Projected Price to Earnings Ratio Cerevel Corp
